Latest news
Iconovo receives order for nasal Covid-19 vaccine development
Biostock published July 16th an article about Iconovo that can be found in its entirety below
Earlier this year, two Swedish life science companies,…
Iconovo receives an order for additional work from ISR for development of a nasal COVID-19 vaccine
Iconovo AB (publ), a company developing complete inhalation products for a global market, today announced that it has received an order from the…
Press releases
May 22, 2023, 08:30
News
IR
English
Regulatory
MAR
Corporate Action
Other
May 22, 2023, 08:30
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
May 11, 2023, 08:30
News
IR
English
Corporate Action
Other
May 11, 2023, 08:30
News
IR
Swedish
Corporate Action
Other
Apr 28, 2023, 09:51
News
IR
Swedish
Correction
Regulatory
MAR
Report
Interim
Q1
mfn-cus-disclaimer
Apr 28, 2023, 08:30
News
IR
Swedish
Regulatory
Listing Regulation
Report
Annual
Apr 28, 2023, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q1
mfn-cus-disclaimer
Apr 20, 2023, 10:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Apr 14, 2023, 08:45
News
IR
Swedish
Corporate Action
Other
Apr 14, 2023, 08:45
News
IR
English
Corporate Action
Other
Apr 04, 2023, 08:15
News
IR
English
Regulatory
MAR
Corporate Action
Other
Apr 04, 2023, 08:15
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Mar 31, 2023, 10:01
News
IR
Swedish
Corporate Information
Other Corporate Information
Mar 16, 2023, 14:30
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
Feb 10, 2023, 11:20
News
IR
Swedish
Corporate Information
Other Corporate Information
Feb 09, 2023, 15:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Feb 08, 2023, 23:59
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 08, 2023, 23:59
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 08, 2023, 17:32
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se